Organization | CAMC Health System

CAMC Health System Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Charleston WV United States (1984)

Organization Overview

First Clinical Trial

2003

NCT00067119

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

CAMC and WVU-Charleston | CAMC Health System | Carol Morreale | Charleston Area Medical Center Health System

Active Ingredients

Drugs in Phase 4 Trials (16)

cefazolin (ancef) (1 trial)

daptomycin (cubicin) (1 trial)

diltiazem (cardizem) (1 trial)

docusate (1 trial)

gabapentin (neurontin) (1 trial)

lidocaine (xylocaine) (4 trials)

lorazepam (ativan) (1 trial)

metoprolol (lopressor) (1 trial)

naloxone (narcan) (1 trial)

nitrofurantoin (furadantin) (1 trial)

pregabalin (lyrica) (1 trial)

prilocaine (citanest) (2 trials)

trimethoprim (1 trial)

valproic acid (depakene) (1 trial)

vancomycin (Vancocin) (2 trials)

Drugs in Phase 3 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (2 trials)

Drugs in Phase 2 Trials (2)

amitriptyline (elavil) (1 trial)

tetracaine (pontocaine) (1 trial)

Drugs in Other Trials (3)

cycloserine (seromycin) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adrenal Insufficiency (Phase 4)

Alcohol Drinking (Phase 4)

Alcoholism (Phase 4)

Atrial Fibrillation (Phase 4)

Atrial Flutter (Phase 4)

Biliary Dyskinesia (Phase 2)

Constipation (Phase 4)

Dyskinesias (Phase 2)

Fistula (Phase 3)

Renal Insufficiency (Phase 3)

Sepsis (Phase 4)

Staphylococcal Infections (Phase 4)

Substance Withdrawal Syndrome (Phase 4)

Thrombosis (Phase 3)

Toxemia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial APIs: 23